Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Louis, Letendre"'
Autor:
Naseema Gangat, Jonathan Bleeker, Douglas Lynch, Horatiu Olteanu, Louis Letendre, Ayalew Tefferi
Publikováno v:
Haematologica, Vol 107, Iss 10 (2022)
Externí odkaz:
https://doaj.org/article/4bf4486a071049c7ba014519af1c89c2
Autor:
Mrinal M. Patnaik, Janice M. Hodnefield, Animesh Pardanani, Louis Letendre, Rhett P. Ketterling, Aref Al-Kali, Naseema Gangat, Curtis A. Hanson, Kebede H. Begna, Ryan A. Knudson, Michelle A. Elliott, William J. Hogan, Taxiarchis Kourelis, Ayalew Tefferi, Mark R. Litzow
Publikováno v:
Mayo Clinic Proceedings. 90:1623-1638
Objectives To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6dd2779b415bb7dd086fa2455503520d
https://doi.org/10.1016/j.mayocp.2015.08.022
https://doi.org/10.1016/j.mayocp.2015.08.022
Autor:
Michelle A. Elliott, Candy S. Peskey, Naseema Gangat, Mrinal M. Patnaik, Kristen B. McCullough, Aref Al-Kali, William J. Hogan, Ross A. Dierkhising, Kristin C. Mara, Jason N. Barreto, Mark R. Litzow, Dennis A. Gastineau, Louis Letendre
The optimal antithrombin(AT) activity parameters for replacement as thromboprophylaxis following asparaginase remains unclear. This single-center, retrospective study evaluated two sets of AT replacement thresholds and targets in adults receiving asp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c122889bd62213ab1603b22ed14ee7db
https://europepmc.org/articles/PMC5546319/
https://europepmc.org/articles/PMC5546319/
Autor:
Donna Jane Hata, Nancy L. Wengenack, Mark R. Litzow, Mark P. Wilhelm, Nathan W. Cummins, Amy J. Wendel, Eric M. Poeschla, Lisa Brumble, Brian D. Lahr, Holenarasipur R. Vikram, Ann E. McCullough, Maheen Z. Abidi, Muhammad R. Sohail, Randall C. Walker, Harshal Shah, Louis Letendre, Shimon Kusne
Publikováno v:
Mycoses. 57:687-698
Summary As invasive mucormycosis (IM) numbers rise, clinicians suspect prior voriconazole worsens IM incidence and severity, and believe combination anti-fungal therapy improves IM survival. To compare the cumulative incidence (CI), severity and mort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c416db096759ec5d45f8940f7e23d13
https://doi.org/10.1111/myc.12222
https://doi.org/10.1111/myc.12222
Autor:
Michelle A. Elliott, Scott H. Kaufmann, Aref Al-Kali, Ming Y. Lim, Animesh Pardanani, Mark R. Litzow, Diane E. Grill, William J. Hogan, Alexandra P. Wolanskyj, Aneel A. Ashrani, Louis Letendre, Kebede H. Begna, Ayalew Tefferi, C. Christopher Hook, Mrinal S. Patnaik, Rajiv K. Pruthi
Publikováno v:
Leukemia & Lymphoma. 54:1263-1267
Central venous access devices (CVADs) are used for intravenous therapy in patients with hematological malignancies. There are limited data comparing catheter outcomes in patients with acute myeloid leukemia (AML) undergoing induction chemotherapy. A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac4effccefaaf8e62794995985cea5e9
https://doi.org/10.3109/10428194.2012.742520
https://doi.org/10.3109/10428194.2012.742520
Autor:
Ayalew Tefferi, Louis Letendre
Publikováno v:
Journal of Clinical Oncology. 30:2425-2428
Current management in acute myeloid leukemia (AML) includes induction chemotherapy followed by several courses of consolidation chemotherapyorallogeneicstem-cell transplantation(SCT).Theexpression 7 3 stands for a combination of intravenous chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e68dcc02d6a5bcdd5e60a966fb05a09d
https://doi.org/10.1200/jco.2011.38.9601
https://doi.org/10.1200/jco.2011.38.9601
Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy*
Autor:
Scott H. Kaufmann, Mark R. Litzow, Ayalew Tefferi, Aneel A. Ashrani, C. Christopher Hook, Louis Letendre, Alexandra P. Wolanskyj, William J. Hogan, Animesh Pardanani, Kebede H. Begna, Michelle A. Elliott, Rajiv K. Pruthi, Aref Al-Kali
Publikováno v:
European Journal of Haematology. 88:237-243
Therapy-related acute promyelocytic leukemia (t-APL) is a well-recognized form of APL for which the underlying etiology has been well characterized. The pathogenesis of de novo (dn-APL) remains unknown; but epidemiologic studies have consistently ide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d638a5ea150a517546a260490134d93f
https://doi.org/10.1111/j.1600-0609.2011.01727.x
https://doi.org/10.1111/j.1600-0609.2011.01727.x
Autor:
Ja Nean K. Engelstad, P. James B. Dyck, Lawrence V. Witt, Joon Shik Moon, Louis Letendre, Peter J. Dyck
Publikováno v:
Journal of the Peripheral Nervous System. 12:286-289
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c836b5787bc5715124559139a5f9d40
https://doi.org/10.1111/j.1529-8027.2007.00151.x
https://doi.org/10.1111/j.1529-8027.2007.00151.x
Autor:
Naseema, Gangat, Mrinal M, Patnaik, Kebede, Begna, Taxiarchis, Kourelis, Aref, Al-Kali, Michelle A, Elliott, William J, Hogan, Louis, Letendre, Mark R, Litzow, Ryan A, Knudson, Rhett P, Ketterling, Janice M, Hodnefield, Curtis A, Hanson, Animesh D, Pardanani, Ayalew, Tefferi
Publikováno v:
Mayo Clinic proceedings. 90(12)
To share our 25 years of experience with patients with primary myelodysplastic syndromes (MDS) and to describe the natural history of the disease including presenting clinical and laboratory characteristics and long-term disease outcomes.One thousand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::deb6f95e51ef7d11e13486b652cd9b22
https://pubmed.ncbi.nlm.nih.gov/26546107
https://pubmed.ncbi.nlm.nih.gov/26546107
Autor:
Sarah F. Paternoster, Stephanie R. Fink, Greg W. Butler, Louis Letendre, A Tefferi, Mark R. Litzow, Stanimir Vuk-Pavlović, Dennis A. Gastineau, Douglas J. Padley, Peggy A. Bulur, Allan B. Dietz, Antje Hoering
Publikováno v:
Cytotherapy. 8:290-298
We conducted a phase I clinical immunotherapy trial of CML to evaluate the safety of a clinical-grade leukemic DC product standardized for purity and mature phenotype.We injected autologous DC into patients in late chronic or accelerated phases of CM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bc725c59a904caa5fe511f903874195
https://doi.org/10.1080/14653240600735743
https://doi.org/10.1080/14653240600735743